Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) regulates the level of SMN expression through ubiquitination in primary spinal muscular atrophy fibroblasts

被引:38
作者
Hsu, Shih-Hsien [1 ]
Lai, Ming-Chi [2 ]
Er, Tze-Kiong [1 ,4 ]
Yang, San-Nan [1 ,3 ]
Hung, Chih-Hsing [1 ,3 ]
Tsai, Hsin-Hung [1 ]
Lin, Yu-Chieh [1 ]
Chang, Jan-Gowth [1 ,4 ,5 ,6 ]
Lo, Yi-Ching [7 ]
Jong, Yuh-Jyh [1 ,3 ,4 ]
机构
[1] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung 80708, Taiwan
[2] Chi Mei Med Ctr, Dept Pediat, Tainan, Taiwan
[3] Kaohsiung Med Univ Hosp, Dept Pediat, Kaohsiung, Taiwan
[4] Kaohsiung Med Univ Hosp, Dept Lab Med, Kaohsiung, Taiwan
[5] Kaohsiung Med Univ, Inst Clin Med, Coll Med, Kaohsiung, Taiwan
[6] Kaohsiung Med Univ, Ctr Excellence Environm Med, Kaohsiung, Taiwan
[7] Kaohsiung Med Univ, Dept Pharmacol, Inst Med, Coll Med, Kaohsiung, Taiwan
关键词
SMA; UCHL1; SMN; Ubiquitination; ZIP TRANSCRIPTION FACTOR; PARKINSONS-DISEASE; POTENTIAL THERAPY; UCH-L1; GENE; PROTEIN; IDENTIFICATION; NEURON; CELLS; SPZ1; DEGRADATION;
D O I
10.1016/j.cca.2010.07.035
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Spinal muscular atrophy (SMA), a lethal hereditary disease caused by mutations of the survival of motor neuron 1 (SMN1) gene, is the leading genetic cause of infant mortality. Its severity directly correlates to the expression level of SMN protein in patients with SMA, but the regulatory mechanisms of SMN protein expression remain incompletely defined. In the present study, we aimed to identify candidate proteins to distinguish SMA fibroblasts from normal fibroblasts. Methods: To identify cellular targets regulating the expression of SMN, we initially utilized a proteomics approach combining 2D electrophoresis and LC-MS/MS, wherein the total proteins extracted from type I SMA patients and normal skin fibroblast cells were compared. Results: Our initial proteomics analysis discovered significant increase of ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) in type I SMA fibroblasts when compared to normal fibroblasts. Significantly, UCHL1 proteins directly interacted with SMN protein, as determined by immunoprecipitation and immunofluorscence assays in P19 and NSC34 cells. Over-expression of UCHL1 in P19 and NSC34 cells significantly reduced the level of SMN proteins in vivo, and, in fact, purified UCHL1 was shown to be able to enhance, in a dose-dependent manner, the level of ubiquitinated SMN in vitro. Further, inhibition of UCHL1 activity by UCHL1 inhibitor (LDN-57444) increased cellular SMN protein and gems number in the nucleus in NSC34 and SMA skin fibroblasts. The same results were observed in cells with UCHL1-specific knockdown. Conclusions: These results suggested that UCHL1 may be a critical regulator in controlling cellular SMN protein turnover, and that it may serve as an attractive therapeutic target for SMA. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:1920 / 1928
页数:9
相关论文
共 44 条
  • [1] Phenylbutyrate increases SMN expression in vitro:: relevance for treatment of spinal muscular atrophy
    Andreassi, C
    Angelozzi, C
    Tiziano, FD
    Vitali, T
    De Vincenzi, E
    Boninsegna, A
    Villanova, M
    Bertini, E
    Pini, A
    Neri, G
    Brahe, C
    [J]. EUROPEAN JOURNAL OF HUMAN GENETICS, 2004, 12 (01) : 59 - 65
  • [2] Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients
    Andreassi, C
    Jarecki, J
    Zhou, JH
    Coovert, DD
    Monani, UR
    Chen, XC
    Whitney, M
    Pollok, B
    Zhang, ML
    Androphy, E
    Burghes, AHM
    [J]. HUMAN MOLECULAR GENETICS, 2001, 10 (24) : 2841 - 2849
  • [3] Altered gene expression in cells from patients with lysosomal storage disorders suggests impairment of the ubiquitin pathway
    Bifsha, P.
    Landry, K.
    Ashmarina, L.
    Durand, S.
    Seyrantepe, V.
    Trudel, S.
    Quiniou, C.
    Chemtob, S.
    Xu, Y.
    Gravel, R. A.
    Sladek, R.
    Pshezhetsky, A. V.
    [J]. CELL DEATH AND DIFFERENTIATION, 2007, 14 (03) : 511 - 523
  • [4] Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy
    Brichta, L
    Hofmann, Y
    Hahnen, E
    Siebzehnrubl, FA
    Raschke, H
    Blumcke, I
    Eyupoglu, IY
    Wirth, B
    [J]. HUMAN MOLECULAR GENETICS, 2003, 12 (19) : 2481 - 2489
  • [5] Regulation of SMN Protein Stability
    Burnett, Barrington G.
    Munoz, Eric
    Tandon, Animesh
    Kwon, Deborah Y.
    Sumner, Charlotte J.
    Fischbeck, Kenneth H.
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2009, 29 (05) : 1107 - 1115
  • [6] Mechanistic studies of ubiquitin C-terminal hydrolase L1.
    Case, A
    Stein, RL
    [J]. BIOCHEMISTRY, 2006, 45 (07) : 2443 - 2452
  • [7] Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part 1: Creatine kinase bb, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1
    Castegna, A
    Aksenov, M
    Aksenova, M
    Thongboonkerd, V
    Klein, JB
    Pierce, WM
    Booze, R
    Markesbery, WR
    Butterfield, DA
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 2002, 33 (04) : 562 - 571
  • [8] Degradation of survival motor neuron (SMN) protein is mediated via the ubiquitin/proteasome pathway
    Chang, HC
    Hung, WC
    Chuang, YJ
    Jong, YJ
    [J]. NEUROCHEMISTRY INTERNATIONAL, 2004, 45 (07) : 1107 - 1112
  • [9] Treatment of spinal muscular atrophy by sodium butyrate
    Chang, JG
    Hsieh-Li, HM
    Jong, YJ
    Wang, NM
    Tsai, CH
    Li, H
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (17) : 9808 - 9813
  • [10] Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases
    Choi, J
    Levey, AI
    Weintraub, ST
    Rees, HD
    Gearing, M
    Chin, LS
    Li, L
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (13) : 13256 - 13264